Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.

Federico Manevy,Gabriele Filkauskas,Pierre Lévy,Judy Fredriksson,Jesse Sussell

Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.

2021

Federico Manevy
Gabriele Filkauskas
Pierre Lévy
Judy Fredriksson
Jesse Sussell

544Background: In patients with HER2-positive early breast cancer (BC), pertuzumab (P) added to trastuzumab (T) and chemotherapy has been recognized as a standard-of-care, improving the risk of rec...

Keywords:

western europe
Medicine
Subcutaneous injection
Internal medicine
Trastuzumab
Chemotherapy
Oncology
drug cost
Pertuzumab
early breast cancer
Fixed-dose combination

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations